APOE2 is associated with longevity independent of Alzheimer's disease
Shinohara M, Kanekiyo T, Tachibana M, Kurti A, Shinohara M, Fu Y, Zhao J, Han X, Sullivan PM, Rebeck GW, Fryer JD, Heckman MG, Bu G. eLife, 2020-10-19
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Combining human cohort data (over 24,000 people) with mouse models, this study found that carrying the APOE2 gene variant is linked to a longer lifespan, and that this benefit holds even when accounting for Alzheimer's diagnosis and brain pathology. In mice, APOE2 extended median lifespan and was linked to preserved activity levels and distinct lipid metabolism. The human longevity association is observational; the underlying mechanism was worked out in animal models, which don't automatically prove the same mechanism operates in people.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 24,661 participants. Carrying the APOE2 variant was linked to longer lifespan in human cohort data, even after accounting for Alzheimer's diagnosis and brain pathology. Its stated limit: The human longevity association is observational; the underlying mechanism demonstrated in mouse models does not automatically prove the same mechanism operates in humans.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shinohara, M., Kanekiyo, T., Tachibana, M., Kurti, A., Fu, Y., Zhao, J., et al. (2020). APOE2 is associated with longevity independent of Alzheimer's disease. eLife.
Vancouver
Shinohara M, Kanekiyo T, Tachibana M, Kurti A, Fu Y, Zhao J, et al. APOE2 is associated with longevity independent of Alzheimer's disease. eLife. 2020.
BibTeX
@article{shinohara2020-685d61d2,
author = {Shinohara, M. and Kanekiyo, T. and Tachibana, M. and Kurti, A. and Fu, Y. and Zhao, J. and Han, X. and Sullivan, P. M. and Rebeck, G. W. and Fryer, J. D. and Heckman, M. G. and Bu, G.},
title = {{APOE2 is associated with longevity independent of Alzheimer's disease}},
journal = {eLife},
year = {2020}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. The record names 12 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Human data (n=24,661) showed APOE2's survival benefit persisted after adjusting for cognitive status, Alzheimer's diagnosis, and cardiovascular factors
- Mice engineered to express human APOE2 had longer median lifespan (911 days) than APOE3 mice (825 days)
- APOE2 mice retained more physical activity with age; higher apoE2 protein levels and altered lipid metabolism correlated with sustained activity
- Findings suggest APOE2 promotes longevity via mechanisms partly independent of amyloid and tau pathology
Why it matters
Carrying the APOE2 variant was linked to longer lifespan in human cohort data, even after accounting for Alzheimer's diagnosis and brain pathology. The human longevity link is observational, and the mechanism was worked out in mice, which does not automatically prove the same mechanism operates in people.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcohort
- Participants24,661
- Effect sizeHuman: survival benefit persisted after adjustment for cognitive status/AD/cardiovascular factors; Mouse: median lifespan 911 days (APOE2) vs. 825 days (APOE3)
- Evidence strengthModerate
Limitations
The human longevity association is observational; the underlying mechanism demonstrated in mouse models does not automatically prove the same mechanism operates in humans.
How this study scored 65/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded and indexed in PubMed because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 40 of the 62 points we could judge it on, which is 65 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (eLife) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 4 / 4 | 24,661 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 0 / 2 | No PubMed ID and no DOI — scores zero (not stated in the record — scored 0) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 40 / 62 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 40 of the 62 points we could judge it on is 65 out of 100. |
| Total | 65 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Genetics from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.